Investigational Drug in Chronic Heart Failure Patients
A pivotal phase 3 randomized, placebo-controlled clinical study to evaluate the efficacy and safety of the sGC stimulator vericiguat/MK-1242 in adults with chronic heart failure with reduced ejection fraction
This clinical trial is exploring the use of an investigational drug (sGC stimulator vericiguat/MK-1242) in patients with chronic heart failure. Specifically, trial doctors are interested in assessing the safety of this drug and if it works well to lower some of the risks of heart failure. All participants will be able to stay on their current heart failure medication during the 2-year trial period.
To evaluate the efficacy of vericiguat compared with placebo in reducing the risk of heart failure hospitalization
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
1) History of chronic stable, NYHA class II to IV CHF
2) NT-proBNP 600 - 6000
3) LVEF of <40% assessed within 12 months before randomization
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the
contact information above or email firstname.lastname@example.org and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality
assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided
in the aforementioned ways, please contact email@example.com.